Curis’s Strategic Clinical Advancements and Promising Data Drive Buy Rating
I'm PortAI, I can summarize articles.
Curis has received a Buy rating from analyst Soumit Roy of JonesTrading, with a price target of $5.00. This rating is based on Curis's upcoming clinical data updates and strategic focus on key trials, particularly in PCNSL and CLL. Promising results from a Phase 1 study of emavusertib in AML patients further support this positive outlook. Significant clinical data is expected at major medical conferences, enhancing Curis's prospects in the healthcare sector.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments